Full Press Release Details
adjuvant libtayo cemiplimab significantly improves disease free survival dfs after surgery in high risk cutaneous squamous cell carcinoma cscc in phase 3 trial.
REGN
adjuvant libtayo cemiplimab significantly improves disease free survival dfs after surgery in high risk cutaneous squamous cell carcinoma cscc in phase 3 trial
Key Takeaway: adjuvant libtayo cemiplimab significantly improves disease free survival dfs after surgery in high risk cutaneous squamous cell carcinoma cscc in phase 3 trial